Tag: court of appeals

  • Juul Buyers Defend Antitrust Classes

    Juul Buyers Defend Antitrust Classes

    Juul purchasers are defending the certification of several antitrust classes before the U.S. Court of Appeals for the Ninth Circuit in litigation stemming from Altria Group’s 2018 investment in Juul Labs. Plaintiffs argue that differences in purchase volumes, transaction terms, and state laws do not prevent the claims from being resolved on a classwide basis. The Ninth Circuit granted review of the class-certification orders in April.

    The litigation involves three named direct purchasers, seven named indirect purchasers, and five named indirect resellers of JUUL products. In February, U.S. District Judge William Orrick of the Northern District of California granted certification to the direct purchaser class and granted portions of the certification motions filed by indirect purchasers and resellers. The plaintiffs allege that an agreement between Altria and Juul restrained competition in the closed-system e-vapor market and resulted in higher prices; Altria and Juul deny the allegations and maintain that the transaction did not violate antitrust laws or produce anticompetitive effects.

    The Ninth Circuit case includes separate appeals concerning the certified classes, with the U.S. Chamber of Commerce also urging the appeals court to reverse the multistate certification. The Chamber has argued that the district court improperly combined California substantive law with damages laws from 26 other states, while the purchasers maintain that the classes satisfy federal requirements for class actions.

  • 5th Circuit Considering if FDA Overstepped in Vape Flavor Regs

    5th Circuit Considering if FDA Overstepped in Vape Flavor Regs

    A three-judge panel of the U.S. Court of Appeals for the Fifth Circuit heard oral arguments this week in a case brought by seven small vape-liquid companies challenging the FDA’s denial of marketing authorization for flavored electronic nicotine delivery systems. The companies argue the FDA rejected their applications based on a comparative efficacy requirement they say was not disclosed before the 2020 PMTA deadline, in violation of the Tobacco Control Act.

    The FDA defended the denials, saying manufacturers must prove their specific products are appropriate for the protection of public health. Government counsel argued that non-tobacco flavors add youth-use risk and that applicants failed to show added adult switching benefits over tobacco-flavored products.

    The panel questioned both sides on whether the FDA’s approach was lawful adjudication or rulemaking in practice. Courthouse News Service said, this “ruling could affect thousands of pending applications and clarify how much procedural leeway the FDA has when reviewing the flood of vape products submitted after the 2020 PMTA deadline.”